Paris, France and Camberley, UK – 2 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a new and innovative portfolio of assays (under the brand name SNPsig®) to aid the diagnosis of the new variants of SARS-CoV-2. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-Variants-launch-02.02.21-ENGLISH.pdf
Visit PageYear: 2021
Lancement d’une gamme de tests de génotypage par PCR pour détecter les variantes de la COVID-19
Paris, France et Camberley, Royaume-Uni – 2 février 2021 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce le lancement d’une gamme innovante de tests (sous la marque SNPsig®) pour aider au diagnostic des nouvelles variantes du virus du SARS-CoV-2. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-Variants-test-02.02.2021-FRENCH.pdf
Visit PageFull Year 2020 Trading Update
Paris, France and Camberley, UK – 29 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2020. http://novacyt.com/wp-content/uploads/2021/01/Novacyt-Trading-Update-29.01.2021-ENGLISH.pdf
Visit Page